New Studies Conducted by PHAR Presented at ISPOR 2018

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Symposium, two of PHAR’s newest studies were presented. One study done in partnership with Akcea Therapeutics estimated helathcare utilization and cost among patients with hereditary transtheyretin amyloidosis (hATTR) by analyzing insurance claims. Another study, in partnership with Otsuka Pharmaceutical, examined the effectiveness of long-acting injectables in reducing psychiatric hospitalization among patients with bipolar I disorder.